

## Clinical Implications

- Hair follicles in younger mice cycle more frequently compared with those in older mice.
- Factors extrinsic to hair follicles can reactivate hair cycling in dormant older skin.
- The secreted protein follistatin enhances hair follicle cycling, pointing to a potential therapeutic strategy for alopecia.

of anagen onset (McDowall *et al.*, 2008). Follistatin gene expression was higher in the skin of younger mice. Further, follistatin levels were increased in older skin grafts following transplantation onto younger mice. As follistatin is a secreted molecule, it may be responsible for the reactivation of hair cycling in telogenic donor skin when grafted onto younger recipients. Strikingly, follistatin-releasing beads were sufficient to convert hair follicles in telogen into anagen when placed on the skin of young mice. Whether this effect can be recapitulated in older mice in telogen retention remains to be seen.

These results support an emerging understanding that aging in skin is not fully a cell autonomous phenomenon. However, as intriguing as these findings are, they raise several new questions. The mechanisms by which follistatin or other extrafollicular signals activate stem cells in the hair bulge are unknown. As follistatin is a known BMP antagonist (McDowall *et al.*, 2008), and as younger mice express higher levels of follistatin, it is tempting to speculate that younger mice are less sensitive to the anagen-inhibitory effects of BMP2. In addition, whether follistatin is the only molecule in young skin capable of rejuvenating older follicles is not clear. Finally, the reason why waves of hair regeneration dissipate in the center of larger skin grafts remains uncertain. It will be interesting to determine whether this reflects intrinsic hair follicle defects or deficiencies in extrinsic signals. These questions aside, the present study is a compelling demonstration that extrafollicular stimuli govern differences in hair renewal capacities in young and old mice. At least when it comes to hair cycling, you really are as young as your neighbors.

### CONFLICT OF INTEREST

The authors state no conflict of interest.

### ACKNOWLEDGMENTS

LAG was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under Award Number R01AR064297.

### REFERENCES

- Alonso L, Fuchs E (2006) The hair cycle. *J Cell Sci* 119:391–3
- Chase HB (1954) Growth of the hair. *Physiol Rev* 34:113–26
- Chen CC, Murray PJ, Jiang TX *et al.* (2014) Regenerative hair waves in aging mice and extra-follicular modulators follistatin,

Dkk1 and Sfrp4. *J Invest Dermatol* 134: 2086–96

Drake DB, Persing JA, Berman DE *et al.* (1993) Calvarial deformity regeneration following subtotal craniectomy for craniosynostosis: a case report and theoretical implications. *J Craniofac Surg* 4:85–9

Garza LA, Yang CC, Zhao T *et al.* (2011) Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. *J Clin Invest* 121:613–22

Kang H, Lichtman JW (2013) Motor axon regeneration and muscle reinnervation in young adult and aged animals. *J Neurosci* 33: 19480–91

Keyes BE, Segal JP, Heller E *et al.* (2013) Nfatc1 orchestrates aging in hair follicle stem cells. *Proc Natl Acad Sci USA* 110:E4950–9

McDowall M, Edwards NM, Jahoda CA *et al.* (2008) The role of activins and follistatins in skin and hair follicle development and function. *Cytokine Growth Factor Rev* 19:415–26

Myung PS, Takeo M, Ito M *et al.* (2013) Epithelial Wnt ligand secretion is required for adult hair follicle growth and regeneration. *J Invest Dermatol* 133:31–41

Plikus MV, Mayer JA, de la Cruz D *et al.* (2008) Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. *Nature* 451:340–4

*See related article on pg 2114*

## Toxic Interaction between Th2 Cytokines and *Staphylococcus aureus* in Atopic Dermatitis

Jeffrey B. Travers<sup>1,2</sup>

Patients with atopic dermatitis (AD) are commonly colonized/infected with *Staphylococcus aureus*, and this bacterium is known to worsen the dermatitis. In this issue, Brauweiler *et al.* demonstrate a newly discovered mechanism by which Th2 cytokines involved in AD augment the toxicity of the lytic staphylococcal protein alpha toxin. This review presents mechanisms by which Th2 cytokines may interact with *S. aureus* to the detriment of the dermatitis.

*Journal of Investigative Dermatology* (2014) 134, 2069–2071. doi:10.1038/jid.2014.122

The vast majority (~90%) of individuals with active atopic dermatitis (AD) are colonized/infected with *Staphylococcus aureus*, a species implicated in worsening the skin disease. The propensity of

these patients to harbor staphylococcal bacteria is thought to be due in part to the inhibitory effects of Th2 cytokines (IL-4, IL-13) on antimicrobial peptide production. Through this mechanism

<sup>1</sup>Richard L. Roudebush VA Medical Center, Indianapolis, Indiana, USA and <sup>2</sup>Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Correspondence: Jeffrey B. Travers, Departments of Dermatology, Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. E-mail: [jtravers@iupui.edu](mailto:jtravers@iupui.edu)

### Clinical Implications

- Staphylococcal infection is a known trigger for worsening of atopic dermatitis skin disease, likely through multiple mechanisms.
- These studies describe a novel mechanism by which Th2 cytokines associated with atopic dermatitis patients can worsen the effects of alpha toxin, a major cytotoxic protein produced by *Staphylococcus aureus*.
- The ability to block the effects of alpha toxin via the use of exogenous acid sphingomyelinase or phosphocholine provides the impetus for novel therapeutics to treat atopic dermatitis patients with chronic skin staphylococcal infections.

and the inhibitory effects of these cytokines on barrier formation, Th2 cytokines provide an environment conducive to bacterial growth.

Given their clinical importance in the management of AD, the mechanisms by which staphylococcal bacteria worsen AD are areas of active study. Staphylococcal bacteria trigger inflammation from direct infection of cell types such as keratinocytes. Staphylococcal products can also exert profound effects via binding to specific receptors. With examples listed in Table 1, these agents include exotoxins that act as superantigens, Staphylococcal protein A (SPA), the cell wall product lipoteichoic acid (LTA), and cytolytic toxins such as staphylococcal alpha toxin and delta toxin. The exact importance of these staphylococcal products in AD associated with infection is, as yet, unknown.

Superantigens including Toxic Shock Syndrome Toxin-1 and Staphylococcal enterotoxin B have significant pro-

inflammatory effects via their abilities to bind to major histocompatibility complex II molecules and activate large numbers of T cells. Relevant to AD, many patients harbor specific IgE antibodies that recognize these large globular proteins (Leung *et al.*, 1993). Thus, superantigen-producing *S. aureus* could generate type I allergic responses via this mechanism. SPA, a surface protein, acts as an important, yet complex, virulence factor contributing to the success of this pathogen by interfering with immune clearance and by modulating inflammation in part via its ability to activate the tumor necrosis factor receptor 1 (TNFR1) directly. Although this would be expected to engender a pro-inflammatory response, recent studies have suggested that through triggering of TNFR1 shedding SPA can actually exert anti-inflammatory effects by the removal of local TNF- $\alpha$  (Giai *et al.*, 2013). The cell wall component LTA has also been implicated in AD inflammation. Recent studies indicate that

large (microgram) amounts of this toll-like receptor 2 and platelet-activating factor receptor agonist are found on the skin of children with secondarily infected AD (Travers *et al.*, 2010).

Staphylococcal bacteria also commonly express at least four cytolytic toxins that appear to have important roles in virulence and in host damage/inflammation. For example, recent studies have determined that delta toxin is a potent inducer of mast cell degranulation (Nakamura *et al.*, 2013). Although IgE is not necessary for delta toxin-mediated mast cell degranulation, the presence of this allergy-associated antibody on mast cell results in exaggerated toxin responses (Nakamura *et al.*, 2013). Thus, AD patients with high levels of IgE in response to Th2 cytokine overactivity would be especially susceptible to delta toxin-mediated effects.

Staphylococcal alpha toxin is one of the most prominent and destructive cytolytic toxins. This pore-forming toxin can act on cell membranes directly, and this process appears to be facilitated via binding to membrane sphingomyelin molecules. Alpha toxin treatment of keratinocytes induces cytokine production, as well as induces cellular death (Ezepchuk *et al.*, 1996; Travers *et al.*, 2003). As reported in this issue, Brauweiler *et al.* (2014) provide evidence that Th2 cytokine exposure can increase the sensitivity of keratinocytes to alpha toxin-mediated cell death. Alpha toxin treatment of skin biopsies derived from AD patients resulted in increased levels of cell death in

Table 1. Mechanisms by which staphylococcal products can modulate AD and the role of Th2 cytokines			
Staphylococcal mediator	Effect on AD skin lesion	Th2 cytokine effect	References
Alpha toxin	Increased keratinocyte cell death and worsening of lesion; increased cytokine production	Increased toxicity via inhibiting filaggrin, acid sphingomyelinase	Brauweiler <i>et al.</i> , 2013, 2014
Delta toxin	Increased mast cell degranulation and worsening of lesion	Increased effect via increased IgE production	Nakamura <i>et al.</i> , 2013
Superantigen (staphylococcal enterotoxin B, toxic shock syndrome toxin-1 ...)	Increased mast cell degranulation and release of cytokines via triggering specific IgE molecules and worsening of lesion	Increased effect via increased IgE production	Leung <i>et al.</i> , 1993
Staphylococcal protein A	Unclear effects; increased inflammation via signaling through TNFR1 versus anti-inflammatory effects via removal of TNF- $\alpha$	Not known	Giai <i>et al.</i> , 2013
Lipoteichoic acid	Increased inflammation via signaling through TLR2 and platelet-activating factor receptor and worsening of lesion	Not known	Travers <i>et al.</i> , 2010
Abbreviations: AD, atopic dermatitis; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor receptor 1.			

comparison with normal skin. The role of Th2 cytokines was then confirmed using keratinocyte primary cultures treated with IL-4/IL-13. In contrast, gamma-INF treatment did not modulate alpha toxin-mediated cytotoxicity. IL-4/IL-13 augmentation of alpha toxin-mediated cytotoxicity was shown to be due to the ability of these Th2 cytokines to decrease the levels of acid sphingomyelinase, the enzyme that cleaves sphingomyelin into ceramide and phosphocholine. The ability of exogenous sphingomyelinase or phosphocholine to reverse the alpha toxin toxicity not only confirmed the mechanisms but also provided the rationale for possible therapeutics.

The authors also demonstrated in a recent companion report that the epidermal barrier protein filaggrin also has an important role in the regulation of acid sphingomyelinase, and that deficiency in filaggrin predisposes for increased alpha toxin-mediated cytotoxicity (Brauweiler *et al.*, 2013). Relevant to Th2 cytokines, IL-4 and IL-13 have also been shown to inhibit filaggrin expression (Howell *et al.*, 2009). Thus, one can envision a positive feedback pathway by which Th2 cytokines not only provide a permissive environment for *S. aureus* but also enhance the effects of staphylococcal products. These findings are compatible with the notion that strategies that remove bacteria, such as dilute bleach baths, can improve AD skin disease (Huang *et al.*, 2009).

In summary, the interplay between Th2 cytokines and *S. aureus* has high significance for understanding AD. Indeed, the majority of AD flares involve *S. aureus* in some capacity. New insights into the exact mechanisms by which staphylococcal exposure can worsen AD could allow improved and novel treatments for this common skin disease and its significant morbidities.

#### CONFLICT OF INTEREST

The author states no conflict of interest.

#### ACKNOWLEDGMENTS

We acknowledge the valuable discussions and proofreading provided by Mark Kaplan, Indiana University, Department of Pediatrics. Support for the author is provided by the National Institutes of Health (HL062996, ES020866) and the Veterans Administration (510BX000853, 1101CX000809).

#### REFERENCES

- Brauweiler A, Goleva E, Leung DY (2014) Th2 cytokines increase *Staphylococcus aureus* alpha toxin induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). *J Invest Dermatol* 134:2114–21
- Brauweiler A, Bin L, Kim BE *et al.* (2013) Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal  $\alpha$ -toxin-induced keratinocyte death. *J Allergy Clin Immunol* 131:421–7
- Ezpechuk YV, Leung DY, Middleton MH *et al.* (1996) Staphylococcal toxins and protein A differentially induce cytotoxicity and release of tumor necrosis factor- $\alpha$  from human keratinocytes. *J Invest Dermatol* 107:603–9
- Giai C, Gonzalez C, Ledo C *et al.* (2013) Shedding of tumor necrosis factor receptor 1 induced by protein A decreases tumor necrosis factor  $\alpha$  availability and inflammation during systemic *Staphylococcus aureus* infection. *Infect Immun* 81:4200–7
- Howell MD, Kim BE, Gao P *et al.* (2009) Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol* 124(3 Suppl 2):R7–12
- Huang JT, Abrams M, Tloutan B *et al.* (2009) Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics* 123:e808–14
- Leung DY, Harbeck R, Bina P *et al.* (1993) Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. *J Clin Invest* 92:1374–80
- Nakamura Y, Oscherwitz J, Cease KB *et al.* (2013) *Staphylococcus*  $\delta$ -toxin promotes allergic skin disease by inducing mast cell degranulation. *Nature* 503:397–401
- Travers JB, Kozman A, Mousdicas N *et al.* (2010) Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid. *J Allergy Clin Immunol* 125:146–52
- Travers JB, Leung DYM, Johnson C *et al.* (2003) Augmentation of staphylococcal alpha toxin signaling by the epidermal platelet-activating Factor receptor. *J Invest Dermatol* 120:789–94

See related article on pg 2122

## A Possible Role for IL-17A in Establishing Th2 Inflammation in Murine Models of Atopic Dermatitis

Nikhil Dhingra<sup>1,2</sup> and Emma Guttman-Yassky<sup>1,3</sup>

Atopic dermatitis (AD) is associated with the effects of T helper type 2 (Th2) and Th22 cytokines. Recent studies, however, have also implicated Th17 in acute AD. Functional studies of Th2 and Th22 cytokines revealed their roles in generating molecular changes during AD; IL-17A's role, however, has yet to be defined. The report by Nakajima *et al.* (this issue) begins to define that role by demonstrating IL-17A's ability to induce Th2 inflammation in acute disease.

*Journal of Investigative Dermatology* (2014) 134, 2071–2074. doi:10.1038/jid.2014.141

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by acute and chronic stages. The pathogenesis of AD is still unclear; both immune- and barrier-driven mechanisms have been demonstrated in murine models and in human disease. AD has been recognized predominantly as a T helper type 2 (Th2)/Th22-centered

disease (Guttman-Yassky *et al.*, 2011). Lesional AD skin is characterized primarily by increased expression of Th2 cytokines and chemokines (IL-4/IL-13, chemokine (C-C motif) ligand (CCL)17, OX40), Th22-related markers (IL-22), as well as Th1- (chemokine (CXC motif) ligand (CXCL10)), Th17- (Elafin/PI3, CXCL1), and Th17/Th22-mediated S100

<sup>1</sup>The Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA;

<sup>2</sup>Columbia University College of Physicians and Surgeons, New York, New York, USA and <sup>3</sup>Department of Dermatology, Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA

Correspondence: Emma Guttman-Yassky, Department of Dermatology, Icahn School of Medicine at Mount Sinai Medical Center, 5 East 98th Street, New York, New York 10029, USA.

E-mail: eguttman@rockefeller.edu